Tranexamic Acid Injection

TRENASE Injection is a Tranexamic Acid Injection which is used in the antifibrinolytic and hemostatic segment. Tranexamic acid helps to control bleeding by slowing the breakdown of blood clots, helping them remain stable when excessive clot breakdown contributes to bleeding. 

Pharma franchise partners can add TRENASE injection to a specialised injectable, hemostatic, surgical-care, or hospital-focused product portfolio. 

Godase Healthcare offers TRENASE injection in 5 x5 ml ampoule packaging. As a prescription injectable, use, sale, storage, and distribution of this injection should follow approved product information and applicable pharmaceutical regulations.  

Profitable PCD Franchise for Tranexamic Acid Injection – Godase Healthcare

Godase Healthcare offers Tranexamic Acid Injection under the brand TRENASE-INJ for businesses looking to expand their specialised injectable and hospital-care product portfolio.

The product may be suitable for PCD pharma franchise partners, pharmaceutical distributors, wholesalers, hospital suppliers, medical representatives, and pharma entrepreneurs who have the required licences and distribution setup.

Interested partners can contact Godase Healthcare to discuss TRENASE-INJ availability, pricing, territory, MOQ, supply, and other PCD business terms.

Additional Product Details:

• Brand Name: TRENASE-INJ
• Composition: Tranexamic Acid
• Dosage Form: Injection
• Therapeutic Category: Antifibrinolytic / Hemostatic
• Product Segment: Injectable / Hospital Care
• Packing: 5 × 5 mL Ampoules
• Target Partners: PCD Pharma Partners, Distributors, Wholesalers, Hospital Suppliers & Pharma Entrepreneurs

Why Add TRENASE Injection to Your PCD Pharma Product Portfolio?

Adding specialised injectable products can help PCD franchise partners to expand beyond tablets, capsules, and syrups.  Key reasons to add TRENASE:

• Specialised Hemostatic Product: Adds Tranexamic Acid Injection to your pharmaceutical portfolio.
• Injectable Form: Suitable for clinical and hospital settings where injectable treatment is prescribed.
• Hospital-Care Portfolio: A useful option for distributors serving hospitals, surgical centres, and institutional buyers.
• Established Molecule: Tranexamic acid is a well-established antifibrinolytic medicine.
• Commercial Packaging: Available in 5 × 5 mL ampoule packaging for pharmaceutical distribution.